Doll, S. ; Proneth, B. ; Tyurina, A.A.* ; Panzilius, E. ; Kobayashi, S. ; Ingold, I. ; Irmler, M. ; Beckers, J. ; Aichler, M. ; Walch, A.K. ; Prokisch, H. ; Trümbach, D. ; Mao, G.* ; Qu, F.* ; Bayir, H.* ; Füllekrug, J.* ; Scheel, C. ; Wurst, W. ; Schick, J. ; Kagan, V.E.* ; Friedmann Angeli, J.P.F. ; Conrad, M.
     
    
        
ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition.
    
    
        
    
    
        
        Nat. Chem. Biol. 13, 91-98 (2017)
    
    
    
      
      
	
	    © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.Ferroptosis is a form of regulated necrotic cell death controlled by glutathione peroxidase 4 (GPX4). At present, mechanisms that could predict sensitivity and/or resistance and that may be exploited to modulate ferroptosis are needed. We applied two independent approaches—a genome-wide CRISPR-based genetic screen and microarray analysis of ferroptosis-resistant cell lines—to uncover acyl-CoA synthetase long-chain family member 4 (ACSL4) as an essential component for ferroptosis execution. Specifically, Gpx4–Acsl4 double-knockout cells showed marked resistance to ferroptosis. Mechanistically, ACSL4 enriched cellular membranes with long polyunsaturated ω6 fatty acids. Moreover, ACSL4 was preferentially expressed in a panel of basal-like breast cancer cell lines and predicted their sensitivity to ferroptosis. Pharmacological targeting of ACSL4 with thiazolidinediones, a class of antidiabetic compound, ameliorated tissue demise in a mouse model of ferroptosis, suggesting that ACSL4 inhibition is a viable therapeutic approach to preventing ferroptosis-related diseases.
	
	
	    
	
       
      
	
	    
		Impact Factor
		Scopus SNIP
		Web of Science
Times Cited
		Scopus
Cited By
		Altmetric
		
	     
	    
	 
       
      
     
    
        Publication type
        Article: Journal article
    
 
    
        Document type
        Scientific Article
    
 
    
        Thesis type
        
    
 
    
        Editors
        
    
    
        Keywords
        Placebo-controlled Trial; Glutathione-peroxidase 4; Focal Cerebral-ischemia; Coa Synthetase 4; Nonalcoholic Steatohepatitis; Therapeutic Target; Death; Pioglitazone; Cancer; Cells
    
 
    
        Keywords plus
        
    
 
    
    
        Language
        
    
 
    
        Publication Year
        2017
    
 
    
        Prepublished in Year
        2016
    
 
    
        HGF-reported in Year
        2016
    
 
    
    
        ISSN (print) / ISBN
        1552-4450
    
 
    
        e-ISSN
        1552-4469
    
 
    
        ISBN
        
    
    
        Book Volume Title
        
    
 
    
        Conference Title
        
    
 
	
        Conference Date
        
    
     
	
        Conference Location
        
    
 
	
        Proceedings Title
        
    
 
     
	
    
        Quellenangaben
        
	    Volume: 13,  
	    Issue: 1,  
	    Pages: 91-98 
	    Article Number: ,  
	    Supplement: ,  
	
    
 
    
        
            Series
            
        
 
        
            Publisher
            Nature Publishing Group
        
 
        
            Publishing Place
            Basingstoke
        
 
	
        
            Day of Oral Examination
            0000-00-00
        
 
        
            Advisor
            
        
 
        
            Referee
            
        
 
        
            Examiner
            
        
 
        
            Topic
            
        
 
	
        
            University
            
        
 
        
            University place
            
        
 
        
            Faculty
            
        
 
    
        
            Publication date
            0000-00-00
        
 
         
        
            Application date
            0000-00-00
        
 
        
            Patent owner
            
        
 
        
            Further owners
            
        
 
        
            Application country
            
        
 
        
            Patent priority
            
        
 
    
        Reviewing status
        Peer reviewed
    
 
     
    
        POF-Topic(s)
        30204 - Cell Programming and Repair
30201 - Metabolic Health
30205 - Bioengineering and Digital Health
30501 - Systemic Analysis of Genetic and Environmental Factors that Impact Health
30203 - Molecular Targets and Therapies
    
 
    
        Research field(s)
        Genetics and Epidemiology
Stem Cell and Neuroscience
Enabling and Novel Technologies
    
 
    
        PSP Element(s)
        G-500500-001
G-500600-004
G-500890-001
G-500390-001
G-500700-001
G-505200-001
    
 
    
        Grants
        
    
 
    
        Copyright
        
    
 	
    
    
    
    
    
        Erfassungsdatum
        2016-11-17